Authors
Kathrine Vandraas, Bjørn Naume, Anna Sætersdal, Egil Blix
Published in
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. Volume 146. Issue 10. Sep 08, 2026. Epub Aug 17, 2026.
Abstract
A major change has taken place in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer in recent decades, largely as a result of the development of targeted anti-HER2 treatment. This type of breast cancer accounts for approximately 13 % of all breast cancer cases diagnosed annually. Treatment options have evolved from a single HER2-targeted monoclonal antibody (trastuzumab) to a range of targeted and potent drugs. Collectively, these advances have led to significant improvements in prognosis and survival for patients with HER2-positive breast cancer. This clinical review outlines the development of HER2-targeted therapies and key principles of current treatment for both localised and metastatic disease.
PMID:
42708992
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0